Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors

NCT04541225 is registered in ClinicalTrials.gov with Nuvation Bio Inc. as lead sponsor.

NCT NCT04541225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04541225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Lead sponsor
Nuvation Bio Inc.
Phase
Phase 1
Overall status
Terminated
Start date
December 8, 2020
Completion date
August 31, 2022
Enrollment
74 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, advanced breast carcinoma, breast cancer, breast carcinoma, breast tumor, cancer of breast, cancer of prostate, cancer of the breast, cancer of the prostate, castrate resistant prostate cancer, castration resistant prostatic neoplasms, castration-resistant prostate cancer, glial cell tumors, glioblastoma, glioma, glioma, malignant, glioma, mixed, malignant tumor of breast, metastatic breast cancer, metastatic breast carcinoma, prostate cancer, prostate neoplasm, prostatic cancer, recurrent glioblastoma